SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Terra is a decentralized financial payment network that rebuilds the traditional payment stack on the blockchain. Luna is the reserve currency of the Terra platform. It has three core functions: i) mine Terra transactions through staking, ii) ensure the price stability of Terra stablecoins and iii) provide incentives for the platform’s blockchain validators.

Terra Luna Classic

Terra Luna Classic is seeing renewed interest as the community rallies behind anticipated network upgrades, burn initiatives, and a shared long-term belief in a potential reversal. Traders are actively discussing the token's low entry point and perceived recovery potential, while comparing its resilience to broader market movements.

Ethereum is a global, open-source platform for decentralized applications. In other words, it is a decentralized blockchain platform that enables developers to build and deploy smart contracts and applications without central authority control. Unlike Bitcoin, which primarily functions as digital currency, Ethereum operates as a programmable global computer where developers can create any type of decentralized service.   The platform hosts over $14 billion in DeFi applications with hundreds of thousands of active users across financial protocols, NFT marketplaces, and gaming platforms. Its transition to Proof of Stake in September 2022 reduced energy consumption by over 99%, addressing environmental concerns while strengthening network security.  The network operates through thousands of independent validator nodes that process transactions and execute smart contracts on the Ethereum Virtual Machine. Smart contracts are self-executing programs written in Solidity that automatically carry out agreements when conditions are met, eliminating intermediaries like banks or brokers.   Validators stake ETH as collateral to propose and validate blocks, earning rewards for honest participation while facing penalties for malicious behavior. The EIP-1559 upgrade introduced a dynamic base fee mechanism that burns ETH with each transaction, creating deflationary pressure during high network activity when more ETH is burned than issued to validators.  Vitalik Buterin proposed Ethereum in 2013, but seven co-founders helped build it, including Gavin Wood who created Solidity and the EVM technical specification, and Joseph Lubin who founded ConsenSys. The project launched in July 2015 after raising over $18 million through crowdfunding, quickly becoming the largest blockchain developer community. Major milestones include the 2020 Beacon Chain launch, the 2021 London hard fork implementing fee burning, and the 2022 Merge to Proof of Stake.   Ether (ETH) serves multiple functions: paying transaction fees (gas), staking to secure the network and earn 3-5% annual yields, serving as collateral in DeFi protocols, and purchasing NFTs and digital assets. The asset is increasingly adopted by traditional institutions, with publicly traded companies adding ETH to corporate treasuries to generate staking yields while maintaining blockchain exposure, and in 2024, the SEC approved spot Ethereum ETFs, allowing traditional investors to gain exposure through conventional brokerage accounts.  Ethereum's roadmap focuses on dramatically increasing transaction capacity to over 100,000 per second, reducing confirmation times, and enhancing decentralization while maintaining security against future threats like quantum computing.

Ethereum

Ethereum is drawing significant attention as investors react to a combination of institutional staking growth and anticipation surrounding potential regulatory developments. The community is actively debating the coin's long-term value, with active discussions focused on navigating market volatility while balancing sentiment between bullish price-appreciation narratives and concerns over liquidity shifts.

"What's Updog?" is a Community Led token.

UpDog

UpDog is generating significant buzz on social media as the Solana-based memecoin maintains steady community momentum and continues to feature prominently on trending lists. Enthusiasts are highlighting its long-term track record, locked liquidity, and ongoing community initiatives like poker nights to foster engagement and promote the project.

KAT is a defi token with governance-like mechanics for Katana.  It is designed to function as a lever for directing capital: users that lock KAT receive a voting version of KAT — vKAT — in return. vKAT underpins key aspects of the chain’s economy, providing rewards to those users that participate. these fee-based rewards function as an incentive for KAT holders to engage in cooperative, positive-sum behavior.

Katana

Katana is trending as traders debate its price action following a recent exchange listing, with the community closely tracking the project's new vKAT tokenomics and ve-style accrual system. While some investors view the asset as a high-potential DeFi utility play, others are expressing caution amidst volatile market movements and discussions regarding future migration plans.

DIEM transforms AI compute from a service you rent into an onchain asset you own: tokenized intelligence. Each Diem token represents $1 per day of Venice API capacity that never expires and never changes value.  DIEM are ERC20 tokens on Base and can be transferred, traded, and staked. DIEM can only be minted by locking staked VVV (sVVV), making DIEM and VVV a foundational assets for onchain AI. Tokenizing intelligence with DIEM creates new possibilities:  Developers/agents: 1 DIEM = $1/day Venice API access, forever VVV holders: Monetize unused compute as DIEM → earn yield → buy back later to unlock VVV Apps: Fixed AI costs, guaranteed capacity, no variable API bills Onchain economy: Agents own their intelligence, DeFi collateralizes compute  Minting DIEM with VVV creates a brand-new onchain building block for AI – programmable, composable compute

Diem

Diem is seeing heightened activity following its listing on Coinbase and ongoing discussions regarding its minting relationship with VVV. Market participants are actively debating the trade-offs between staking strategies and direct token accumulation as the ecosystem scales.

JasmyCoin is based on the ERC 20 standard. The token can also be used by an unspecified number of individuals and businesses to transfer tokens using digital devices as proof of value exchange or payment for services. By not limiting its usability, the token can have a wide range of purposes.

JasmyCoin

JasmyCoin remains a highly polarized asset on social media, with investors debating its long-term potential amid frustrations over stagnant price action and minimal communication from leadership. While some community members continue to accumulate aggressively, viewing current levels as a strategic buying opportunity for future cycles, others express deep skepticism and frustration regarding its performance relative to the broader crypto market.

Jupiter is a cryptocurrency exchange platform on the Solana blockchain, offering features such as token swapping, limit orders, dollar-cost averaging, and a bridge for asset transfers to Solana. It provides users with tools to find the best trading prices and includes a beta version for perpetual futures trading. Jupiter finds the best price route for your swap by aggregating all the major liquidity sources on Solana.

Jupiter

The community surrounding $UPDOG is actively highlighting the project's longevity on Solana and its presence on the Jupiter strict list, encouraging users to swap via JUP. Traders are also discussing broader market sentiment and utilizing JUP's lending features, despite some community frustration regarding exchange volatility and platform performance.

Magnachip Semiconductor Corp. engages in the design and manufacture of analog and mixed-signal platform solutions for communications, Internet of Things (IoT), consumer, computing, industrial, and automotive applications. Its products include MOSFETs, IGBTs, AC-DC/DC-DC converters, light-emitting diode (LED) drivers, regulators, power management integrated circuits (PMICs), and industrial applications such as power suppliers, e-bikes, photovoltaic inverters, LED lighting, and motor drives. The company was founded on November 26, 2003 and is headquartered in Cheongju-si, South Korea.

MagnaChip Semiconductor Corp

MagnaChip Semiconductor is currently a focal point for investors due to its attractive valuation and active share buyback program, which recently saw an expansion to $87.5 million. The community is actively debating the likelihood of a strategic buyout or merger, particularly with persistent rumors surrounding potential interest from South Korean conglomerates.

Relay Therapeutics, Inc. engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology. Its Dynamo platform is use to integrate an array of edge experimental and computational approaches, which allows to apply the understanding of protein structure and motion to drug discovery. The company was founded by David Elliot Shaw, Matthew P. Jacobson, Dorothee Kern, Mark Murcko, Alexis Borisy, and Jakob Loven on May 4, 2015 and is headquartered in Cambridge, MA.

Relay Therapeutics Inc

Relay Therapeutics is currently trending as institutional investors and the community weigh the potential for a multi-billion dollar acquisition, driven by the presence of a board experienced in major pharmaceutical buyouts and an upcoming clinical data catalyst in May. Market participants are closely monitoring the high concentration of institutional ownership and a substantial short position, which is fueling intense speculation regarding a potential structural breakout or buyout offer from major industry players like Pfizer or Novartis.

iShares Bitcoin Trust ETF (The) - iShares Bitcoin Trust Beneficial Interest

iShares Bitcoin ETF

IBIT is drawing significant attention as institutional inflows remain robust despite broader market volatility, with the community actively debating whether Bitcoin's resilience amid geopolitical tensions signals a decoupling from traditional risk assets. Traders are closely monitoring heavy options activity and institutional accumulation patterns, as many look for confirmation of a durable bottom.

statis crypto Watchlist

Bitcoin

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

FDA Clears NVO's Higher Dose of Wegovy: Diversify With These Health ETFs

Novo Nordisk's FDA nod for higher-dose Wegovy could boost healthcare ETFs' appeal, offering diversified exposure to the obesity drug market.

<ul class="summary-bullets"><li>Glenmark launched semaglutide under the brand name GLIPIQ for adults with Type 2 diabetes at ₹325 ($3.5) per week on Saturday.</li><li>The launch comes in a market where GLP-1 drugs such as Ozempic and Mounjaro are available at a much steeper cost.</li><li>The lower price point will reduce the cost barrier for diabetes and weight-loss treatment in India.</li></ul>As demand for diabetes and weight-loss treatments rises, Glenmark Pharmaceuticals Ltd (GLENMARK.NSE) has introduced a cost-effective version of semaglutide in India, aiming to improve affordability in a market dominated by higher-priced alternatives.Glenmark&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://glenmarkpharma.com/gpl_pdfs/media/PR_Glenmark%20Pharmaceuticals%20launches%20GLIPIQ%E2%93%87.pdf">launched</a> semaglutide under the brand name GLIPIQ for adults with Type 2 diabetes on Saturday, with weekly treatment costs starting at ₹325 ($3.5). The drug belongs to a class of medicines that help control blood sugar levels and are also used for weight management.The launch came in the market as GLP-1 drugs like Ozempic and Mounjaro are available at significantly higher prices. Weekly treatment using these can cost around ₹3,000 ($21) or more, depending on dosage and brand. At a more granular level, a 1 mg dose of Ozempic is priced near ₹12,000 ($128), while a 2.5 mg Mounjaro injection costs about ₹3,300 ($35).In comparison, GLIPIQ is priced between ₹325 and ₹440 ($3.5 to $4.7) per week, depending on dosage.Commenting on the launch, Alok Malik, President and Business Head, India Formulations at Glenmark Pharmaceuticals, said, “Affordability is one of the biggest barriers to initiating advanced diabetes treatment in India. With GLIPIQ, we are setting a new benchmark in affordability for GLP-1 drugs, with weekly treatment starting at ₹325.”<a href="https://stocktwits.com/symbol/GLENMARK.NSE/sentiment">GLENMARK.NSE</a> closed at ₹2,180 ($23.19) on Friday, trading up by almost 4%. On Stocktwits, the retail sentiment around GLENMARK.NSE improved from ‘neutral’ to ‘bullish,’ as chatter levels around it remained ‘normal’ over the past day.<figure class="image"><img src="https://news.stocktwits-cdn.com/Screenshot_2026_03_21_at_2_24_01_PM_png_9e2a9418ca.webp" alt="Screenshot 2026-03-21 at 2.24.01 PM.png" width="1160" height="684"><figcaption>StocktwitsGLENMARK.NSE retail sentiment on March 21 as of 2:42 a.m. ET | Source: Stocktwits</figcaption></figure><h2 class="st-heading-2">Global GLP-1 Market</h2>The GLP-1 drug market has been dominated by Novo Nordisk (NVO) and Eli Lilly (LLY), whose products Ozempic and Monjaro are widely used for diabetes and weight management. However, patent expiries have reshaped the landscape.&nbsp;According to a Bloomberg&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.bloomberg.com/news/articles/2026-03-20/ozempic-copies-to-cost-14-in-india-as-generic-glp-1-era-starts">report</a>, Canada was among the first to lose patent protection for semaglutide earlier this year. The patent for semaglutide is also set to expire this month in China, Brazil, and Turkey. This positioned India as one of the first major markets to see the entry of lower-cost alternatives, as domestic drugmakers began launching competing products at a much lower cost.&nbsp;<h2 class="st-heading-2">How Is Stocktwits Reacting?</h2><stembedurl>https://www.stocktwits.com/TrendonomicsHD/message/648064809</stembedurl>One user on Stocktwits said that Glenmark is showing strong bullish technical signals despite a bearish sentiment. They pointed out that the stock appears to be in a "Stage 2 breakout," meaning it is starting to edge higher.Read also: <a href="https://stocktwits.com/news-articles/markets/cryptocurrency/bitcoin-whale-who-called-crash-warns--debt-hits-wwii/cZ3i55RRIiW">Whale Who Shorted Bitcoin In Black Swan Event Warns As US Debt Hits Highest Since World War II</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Ozempic is medicine for adults with type 2 diabetes that along with diet and exercise may improve blood sugar. While some doctors are prescribing it "off label" for weight loss, on March 17, 2026 in Sydney, Australia. (Photo by Steve Christo/Getty Images)

Glenmark Debuts Budget Semaglutide In India, Undercutting Ozempic By Over 80%

As the patents for semaglutide near expiry in several countries this month, India has introduced a cost-effective alternative.

Equity

As the patents for semaglutide near expiry in several countries this month, India has introduced a cost-effective alternative.


<ul class="summary-bullets"><li>Orforglipron showed greater reductions in A1C blood sugar levels and body weight compared with the oral semaglutide.</li><li>Lilly has filed the drug for approval in more than 40 countries and plans to submit it in the U.S. later this year.</li><li>Eli Lilly is poised to lead the fast-growing GLP-1 market, JPMorgan Chase analyst Chris Schott reportedly said on Wednesday.</li></ul>Eli Lilly and Company (LLY) announced on Thursday that its experimental diabetes pill, Orforglipron, outperformed oral semaglutide in a large Phase 3 study, delivering stronger reductions in blood sugar and greater weight loss over 52 weeks.&nbsp;The 52-week ACHIEVE-3 trial enrolled 1,698 adults with type 2 diabetes and included four treatment groups - Orforglipron at 12 mg and 36 mg doses, and oral semaglutide at 7 mg and 14 mg doses.&nbsp;<a href="https://stocktwits.com/symbol/LLY">LLY shares</a> were up 0.3% in pre-market trading.<h2 class="st-heading-2">Greater Reductions In A1C Blood Sugar Levels And Body Weight</h2>According to Lilly, Orforglipron showed greater reductions in A1C blood sugar levels and body weight compared with the oral semaglutide. The company said that the results were published in The Lancet. This study comes as the oral GLP-1 race intensifies across the sector.Orforglipron delivered meaningful improvements in several key heart health measures, including cholesterol levels, blood pressure, and triglycerides. Its safety profile in the ACHIEVE-3 study was consistent with that observed in earlier trials.The most common side effects for both orforglipron and oral semaglutide were nausea, diarrhea, vomiting, indigestion, and reduced appetite. However, discontinuation rates due to side effects were slightly higher with orforglipron compared to oral semaglutide.Lilly has filed the drug for approval in more than 40 countries and plans to submit it in the U.S. later this year.“The results of ACHIEVE-3 highlight the potential advantages of Orforglipron over oral semaglutide for type 2 diabetes: greater A1C reduction, more weight loss, and the ability to take it without food or water timing restrictions — that’s a combination that could matter significantly to people managing their disease day in and day out,” said Kenneth Custer, Ph.D., executive vice president and president of Lilly Cardiometabolic Health.<h2 class="st-heading-2">Lilly To Lead GLP-1 Market, JPMorgan Says</h2>Eli Lilly is poised to lead the fast-growing GLP-1 market, JPMorgan Chase analyst Chris Schott reportedly said. According to a CNBC article on Wednesday, Schott said Lilly’s “best-in-class” position and its direct-to-consumer platform, LillyDirect, could help it beat expectations as demand for weight-loss drugs rises.Schott estimates that by 2030, about 8 million patients could pay cash for GLP-1 treatments, benefiting Lilly. He also sees further upside when Lilly launches its oral drug. When Medicare begins covering GLP-1s in April, Schott believes Lilly will gain the most, with 4.5 million Medicare patients projected to use the drugs by 2030.Retail sentiment on Stocktwits remained ‘neutral’ over the past 24 hours.Year-to-date, the stock has fallen around 5%.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/array-arry-stock-crashes-pre-market-200-dma-q4-results/cZTGfpIRIbu">ARRY Stock Cracks 26%, On Track To Hit 200-DMA For First Time In 3 Months – Retail Says Valuation Is ‘Cheap’</a> For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, an Eli Lilly and Company logo seen displayed on a smartphone. (Photo Illustration by Igor Golovniov/SOPA Images/LightRocket via Getty Images)

Eli Lilly’s Diabetes Pill Outperforms Oral Semaglutide in Phase 3 Trial

Investors are closely watching the oral GLP-1 race as competition intensifies across the sector.

Eli Lilly’s Oral GLP-1 Pill Showed Stronger A1C Drop, Weight Loss Than Oral Semaglutide 

<ul class="summary-bullets"><li>Vivtex will license select drug-delivery technologies to Novo Nordisk and could receive up to $2.1 billion.</li><li>The partnership looks to enable biologic drugs, which are typically given by injection due to poor absorption, to be delivered orally.</li><li>This partnership comes a day after Novo announced plans to cut U.S. prices for Ozempic and Wegovy by up to 50% from 2027.</li></ul>Novo Nordisk (NVO) announced on Wednesday that it has partnered with Vivtex Corp. to develop next-generation oral biologic medicines for obesity, diabetes, and related conditions.Under the agreement, Vivtex will license select oral drug-delivery technologies to Novo Nordisk and could receive up to $2.1 billion in upfront payments, research funding, milestones, and tiered royalties on future sales.“Partnering with Novo Nordisk allows us to apply our platform across important metabolic disease areas, with the goal of enabling oral therapies that would otherwise require injection,” said Thomas von Erlach, CEO and co-founder of Vivtex.<a href="https://stocktwits.com/symbol/NVO">NVO shares</a> were down 1.8% at the time of writing.<h2 class="st-heading-2">Focus On Oral Delivery</h2>The partnership combines Novo’s expertise in peptide and protein therapies with Vivtex’s gastrointestinal screening tools, drug-delivery technologies, and AI-based platform aimed at improving drug absorption.The collaboration aims to enable biologic drugs, which are typically given by injection due to poor absorption, to be delivered orally. Novo Nordisk will lead global development, regulatory approval, manufacturing, and commercialization of any resulting products, it said.Oral obesity pills are seen as a key focus area in the obesity market, eliminating the need for injections and giving patients greater flexibility.This comes a day after Novo Nordisk <a href="https://stocktwits.com/news-articles/markets/equity/novo-nordisk-cut-ozempic-wegovy-prices-by-50/cZRvxJeR4C2">announced</a> plans to cut U.S. prices for Ozempic and Wegovy by up to 50% starting in 2027.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment on Stocktwits remained in the ‘extremely bullish’ zone over the past 24 hours, amid ‘extremely high’ message volumes.One user sees the stock as a “short-term buy” option.<stembedurl>https://stocktwits.com/buddyopalosam/message/645859049</stembedurl>Another user said the stock was ‘undervalued.’<stembedurl>https://stocktwits.com/Matt_Y_/message/645842315</stembedurl>Year-to-date, the stock is down around 27%.For updates and corrections, email newsroom[at]stocktwits[dot]com.&nbsp;

In this photo illustration, the logo of Novo Nordisk is displayed on a smartphone screen on September 10, 2025 in Chongqing, China. 

Novo, Vivtex Ink $2.1 Billion Deal To Develop Oral Medicines For Obesity And Diabetes

Novo Nordisk will lead global development, regulatory approval, manufacturing, and commercialization of the resulting products.

<ul class="summary-bullets"><li>The Danish pharmaceutical giant is expanding operations at its Athlone site.</li><li>CEO Mike Doustdar did not disclose how much the company plans to spend.</li><li>&nbsp;Doustdar said more than 240,000 people in the U.S. have already begun taking Wegovy in the form of pills.</li></ul>Novo Nordisk (NVO) is reportedly planning to ramp up its manufacturing footprint in Ireland as it prepares to increase production of its blockbuster Wegovy weight-loss pill for patients outside the U.S.&nbsp;According to a Bloomberg&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.bloomberg.com/news/articles/2026-02-12/novo-set-to-make-wegovy-pill-in-ireland-for-markets-outside-us?srnd=homepage-americas">report</a>, Novo’s CEO, Mike Doustdar, said the company will expand its facility in Ireland’s midlands region to support international demand for the oral version of Wegovy.Doustdar did not disclose how much the company plans to spend but emphasized that the expansion signals confidence in the product’s global prospects. The Danish pharmaceutical giant is expanding operations at its site in Athlone, a move that underscores its renewed push in the highly competitive obesity drug market.<a href="https://stocktwits.com/symbol/NVO">Novo Nordisk stock</a> inched 0.6% higher in Thursday’s premarket. On Stocktwits, retail sentiment around the stock remained in ‘bearish’ territory while message volume shifted to ‘normal’ from ‘high’ levels in 24 hours.&nbsp;<h2 class="st-heading-2">Strong Early Demand</h2>The report cited that Wegovy’s pill form debuted in early January and quickly gained traction. Doustdar said more than 240,000 people in the U.S. have already begun taking the medication, calling it one of the most successful rollouts in the industry.Novo manufactures the U.S. supply domestically, while the Irish site will focus on serving markets beyond the U.S. On Wednesday, Doustdar said the company is planning to offer Wegovy injectables in vial form, similar to what competitor Eli Lilly and Company (LLY) has done.The latest push in Ireland comes as Novo works to regain momentum in the weight-management segment it once led. The company had previously warned about several challenges in 2026, including intense competition, lower selling prices, and the loss of patent protection for the main ingredient in its drugs, Wegovy and Ozempic, in some countries outside the U.S.NVO stock has declined by over 40% in the last 12 months.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/rivian-stock-rises-premarket-ahead-of-q4-earnings-r2-suv-reveal-nears-benchmark-sees-upside/cZRThmWR4AC">Rivian Stock Rises Premarket Ahead Of Q4 Earnings As R2 SUV Reveal Nears — Benchmark Sees Over 20% Upside</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

The Novo Nordisk logo is seen with tablets, capsules, and syringes in this photo illustration in Brussels, Belgium, on August 9, 2025. 

Novo Looks To Ireland To Scale Production Of Wegovy Pill: Report 

According to a Bloomberg report, Novo’s CEO, Mike Doustdar, said the company will expand its facility in Ireland’s midlands region to support international demand for the oral version of Wegovy.

<ul class="summary-bullets"><li>GDNF outperformed semaglutide, the active ingredient in Wegovy and Ozempic, across several key measures, Hoth said.</li><li>The 12-week study showed that female mice on a high-fat diet experienced a 10% to 15% reduction in weight gain with GDNF, whereas semaglutide showed no meaningful effect.</li><li>The company said GDNF reduced liver weight by 20% to 30% and prevented fat buildup, highlighting its potential to address fatty liver disease.</li></ul>Hoth Therapeutics (HOTH), on Tuesday, announced preclinical results from a Veterans Administration-backed study evaluating glial cell-derived neurotrophic factor (GDNF) as a potential treatment for obesity and metabolic-associated steatotic liver disease (MASLD).The company stated that in a head-to-head comparison, GDNF outperformed semaglutide, the active ingredient in weight-loss drugs such as Wegovy and Ozempic, across several key measures, including weight control, glucose tolerance, liver weight reduction, and adipose tissue control.<a href="https://stocktwits.com/symbol/HOTH">HOTH shares</a> were up over 5% in pre-market trading but reversed gains after the opening bell, trading 6% lower.<h2 class="st-heading-2">What Did The 12-Week Study Show?</h2>During the 12-week study, female mice on a high-fat diet experienced a 10% to 15% reduction in weight gain with GDNF, eventually entering a stabilization phase, whereas semaglutide showed no meaningful effect. Researchers noted that higher doses or longer durations could amplify GDNF’s effects.GDNF also normalized fasting glucose levels and improved responses to glucose challenges. Additionally, the therapy reduced liver weight by 20% to 30% and prevented fat buildup, highlighting its potential to address fatty liver disease, a common issue with obesity.“These results are a monumental step forward for Hoth and the fight against obesity. GDNF not only matched but exceeded semaglutide in critical areas, opening doors to a new era of safer, more effective therapies,” said Robb Knie, CEO of Hoth Therapeutics.<h2 class="st-heading-2">What’s Next?</h2>Hoth plans additional studies on liver pathology, lipid content, and gene and protein expression to better understand GDNF’s mechanism, with clinical trials targeted for 2027.Weight-loss drugs have become a central focus for the pharmaceutical industry, driving revenue growth for leaders like Eli Lilly and Novo Nordisk as other companies race to enter the booming market.The segment has been under regulatory spotlight in the aftermath of Hims &amp; Hers launching a compounded version of Wegovy last week, which the company has since withdrawn following legal notices from NOVO and the U.S. Food and Drug Administration.&nbsp;&nbsp;<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment turned ‘bullish’ from ‘neutral’ a day earlier, accompanied by ‘high’ message volumes.<img src="https://news.stocktwits-cdn.com/HOTH_jpg_40deb046fb.webp" alt="HOTH.jpg">One user called for patience amid the intraday decline.<stembedurl>https://stocktwits.com/Tom678/message/644546402</stembedurl>HOTH shares are down around 21% so far this year.Read also: <a href="https://stocktwits.com/news-articles/equity/markets/why-did-azi-stock-reverse-gains-in-premarket/cZbUIHFR4Yy">AZI Stock Reverses Early Gains To Slump 30% In Pre-Market – What Happened?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

06 February 2025, Baden-Württemberg, Rottweil: A candlestick chart is opened in a trading platform on a smartphone. Photo: Silas Stein/dpa

Hoth Therapeutics' GDNF Treatment Shows Superior Efficacy Over Wegovy, Ozempic In Preclinical Trial

The company announced positive preclinical results from a study evaluating GDNF as a potential treatment for obesity and metabolic-associated steatotic liver disease.

<ul class="summary-bullets"><li>Hims &amp; Hers said the compounded copy uses the same active ingredient as Wegovy but features a different formulation and delivery system.</li><li>The compounded pill will start at the introductory pricing for the first month for qualifying new customers under a five-month plan.</li><li>The pill is engineered to preserve the active ingredient during digestion and improve absorption.</li></ul>Shares of Hims &amp; Hers Health, Inc. (HIMS) rose 10% on Thursday after the company announced the launch of a compounded copy of the Wegovy weight-loss pill at an introductory price of $49 per month.Hims &amp; Hers said the compounded copy uses the same active ingredient as Wegovy but features a different formulation and delivery system from the FDA-approved oral semaglutide. Novo Nordisk originally introduced Wegovy as a once-weekly injection and expanded the franchise earlier this year with the launch of an oral pill version.<h2 class="st-heading-2">$100 Cheaper Than Novo’s Wegovy</h2>Hims &amp; Hers said treatment plans using the compounded pill will start at an introductory $49 for the first month for qualifying new customers under a five-month plan. The remaining months are priced at $99 per month, payable in advance.According to Novo Nordisk’s website, Wegovy pills are priced at $149 per month for a 1.5 mg dose.Hims &amp; Hers stated that its compounded pill is engineered to preserve the active ingredient during digestion and improve absorption, offering an alternative for patients who want to avoid injections.Meanwhile, NVO shares fell nearly 6%.<h2 class="st-heading-2">Novo’s Pricing Challenges</h2>Earlier this week, Novo said it expects adjusted sales for full year 2026 to drop between 5% and 13%, with operating profit potentially falling by 13% due to pricing pressure, intensifying competition, and upcoming patent expiries for key ingredients in Wegovy and Ozempic in select markets outside the U.S.“Our 2026 guidance reflects a year of unprecedented pricing pressure,” CEO Mike Doustdar said in a call with journalists on Wednesday. Doustdar added that Novo would have to accept short-term pain to lift volumes, arguing that lowering prices would pay off in the long-run.The pill variant has already seen significant traction since its launch in January.“I can tell you, as of this week, we have over 170,000 people that are on the Wegovy pill, and most of that is self-pay,” Doustdar said in a call with analysts.Eli Lilly (LLY), the maker of weight-loss drugs Mounjaro and Zepbound, saw its shares fall 6.5%.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment for <a href="https://stocktwits.com/symbol/HIMS">HIMS</a> on Stocktwits turned ‘extremely bullish’ from ‘bullish’ a day earlier, while chatter was ‘extremely high’ on the platform.One user saw the new launch as a “trend changing event.”<stembedurl>https://stocktwits.com/Dr_Stoxx/message/644091407</stembedurl>Another bullish user highlighted HIM’s latest developments.<stembedurl>https://stocktwits.com/tothebulltothewall/message/644092695</stembedurl>Year-to-date, the stock has declined around 20%.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/why-b-stock-is-falling-despite-q4-beat/cZbZB3uR4VV">Barrick’s Q4 Earnings Beat Expectations – So, What Is Dragging The Stock Down In Premarket Today?</a> For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, a smartphone displays the logo of Hims & Hers Health in front of a screen showing the company's stock market chart. (Photo illustration by Cheng Xin/Getty Images)

HIMS New $49 Pill Lifts Stock 10%, But Why Are NVO, LLY Stocks Falling?

The company announced the launch of a compounded copy of the Wegovy weight-loss pill at an introductory price of $49 per month.

HIMS Stock Rises On Low-Cost Wegovy Alternative, Raising New Pricing Questions For Novo And Lilly

The company announced the launch of a compounded copy of the Wegovy weight-loss pill at an introductory price of $49 per month.



Healthcare ETFs to Watch as Novo Nordisk Tumbles on Poor Sales Outlook

Novo Nordisk slides 15% on a cautious 2026 sales outlook, but buybacks, leadership moves and Wegovy expansion put its ETFs in focus.

<ul class="summary-bullets"><li>In an interview with CNBC on Wednesday, CEO Doustdar said people should expect the company’s share price to go down before it goes back up.</li><li>NVO shares fell 4.5% in pre-market trading on Wednesday, extending Tuesday’s losses after the drugmaker issued a weak outlook for fiscal 2026.</li><li>Novo attributed the outlook to pricing pressure, and rising competition.</li></ul>Novo Nordisk (NVO) expects the U.S. Food and Drug Administration to decide on a higher-dose version of its Wegovy weight-loss drug in the first quarter of fiscal 2026.“Novo Nordisk submitted the high-dose semaglutide 7.2mg to the FDA in November. It’s under the CNPV pilot program, and we anticipate a decision during the first quarter of 2026,” Novo’s CEO Mike Doustdar said in a call with analysts on Wednesday.Novo Nordisk submitted a supplemental New Drug Application (NDA) to the FDA in November, and under the Commissioner’s National Priority Voucher expedited program, a review decision is usually expected within one to two months after the filing is accepted.<a href="https://stocktwits.com/symbol/NVO">NVO shares</a> were down 4.5% in pre-market trading on Wednesday.<h2 class="st-heading-2">Weak 2026 Outlook Weighs On Shares&nbsp;</h2>The stock extended Tuesday’s losses of over 14% after the drugmaker issued a soft outlook for fiscal 2026, warning that sales and profit growth could decline amid mounting industry pressures. The company expects adjusted sales to fall between 5% and 13%, and operating profit could decline by up to 13%.Novo attributed the outlook to pricing pressure, rising competition, and upcoming patent expiries for the active ingredients in blockbuster drugs Wegovy and Ozempic in certain markets outside the U.S.In an interview with CNBC on Wednesday, Doustdar said people should expect the company’s share price to go down “before it comes back up.”The cautious forecast follows a disappointing 2025 performance. Novo reported net sales of DKK 309.06 billion ($48.9 billion), up 6% year over year but well below analyst estimates of DKK 346.97 billion.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Despite the intraday decline, retail sentiment on Stocktwits turned ‘bullish’ from ‘bearish’ a day earlier, amid ‘extremely high’ message volumes.<figure class="image"><img src="https://news.stocktwits-cdn.com/NVO_jpg_0be70277b2.webp" alt="NVO.jpg" width="931" height="105"><figcaption>NVO's Sentiment Meter and Message Volumes at Premarket on Feb. 4, 2026 | Source: Stocktwits</figcaption></figure>One user said that the bearish guidance was a “self-inflicted wound.”<stembedurl>https://stocktwits.com/DJEuphoria/message/643918854</stembedurl>However, another user highlighted Novo’s strong grip in the diabetes and obesity markets.<stembedurl>https://stocktwits.com/Valconomics/message/643892305</stembedurl>NVO shares have plummeted around 40% over the past year.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/eli-lilly-lly-stock-jumps-fy26-guidance-zepbound-mounjaro/cZbSCjgR4Zl">LLY Stock Surges Pre-Market: Obesity, Diabetes Drugs Drive Strong FY26 Outlook</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Novo Awaits FDA Call On Higher-Dose Wegovy In Early 2026 – NVO Stock Extends Decline Pre-Market On Weak Guidance

Novo Nordisk submitted a supplemental New Drug Application (NDA) to the FDA in November, and under the CNPV program, a review decision is usually expected within one to two months after the filing is accepted.

Novo Awaits FDA Call On Higher-Dose Wegovy In Early 2026 – NVO Stock Extends Decline Pre- Market On Weak Guidance

<ul class="summary-bullets"><li>Eli Lilly issued a revenue guidance between $80 billion and $83 billion for fiscal 2026</li><li>For the full year 2025, Eli Lilly’s revenue grew 45% to $65.18 billion.</li><li>CFO Lucas Montarce said the company expects to launch the multidose Zepbound within the next 30 days, according to a Bloomberg report.</li></ul>Shares of Eli Lilly (LLY) jumped 8% in pre-market trading on Wednesday, after the company reported better-than-expected fourth-quarter results and issued a revenue guidance between $80 billion and $83 billion for fiscal 2026, significantly above fiscal 2025 revenue.<a href="https://stocktwits.com/symbol/LLY">LLY shares</a> were up 9.2% after the opening bell.Fourth-quarter revenue surged 43% to $19.3 billion, driven by volume growth from Mounjaro and Zepbound – signalling sustained momentum in its obesity and diabetes portfolio. Analysts had expected a revenue of $17.86 billion, according to Fiscal.ai data. Meanwhile, Q4 earnings increased by 51% to $7.39 per share on a reported basis, compared to Street estimates of $7.22 per share.For the full year, Eli Lilly’s revenue grew 45% to $65.18 billion. LLY expects earnings of $33.50 to $35 per share for full-year 2026.<h2 class="st-heading-2">Mounjaro And Zepbound Drive Revenue Growth</h2>Global revenue for Mounjaro surged 110% to $7.4 billion in Q4 2025, with U.S. sales rising 57% to $4.1 billion on strong demand despite lower realized prices. International revenue jumped to $3.3 billion from $899 million a year earlier, driven mainly by volume growth.U.S. Zepbound revenue climbed 122% to $4.2 billion, fueled by higher demand but partially offset by pricing pressure. Meanwhile, revenue from Verzenio, Eli Lilly’s drug to treat metastatic breast cancer, edged up 3% to $1.6 billion.<h2 class="st-heading-2">Eli Lilly’s Product Pipeline</h2>After the FDA authorized Lilly to market Zepbound in a multidose device last month, CFO Lucas Montarce said the company expects to launch the multidose pen within the next 30 days, according to a report by Bloomberg on Wednesday.In an interview with CNBC last month, CEO Dave Ricks said the upcoming Medicare coverage for obesity drugs could significantly boost the launch of its experimental weight-loss pill, Orforglipron. Ricks added that the company expects Medicare coverage to begin immediately after the drug’s launch.<h2 class="st-heading-2">LLY Pulls Ahead As NOVO Faces Headwinds</h2>Eli Lilly’s optimistic outlook stands in stark contrast to Novo Nordisk (NVO), which expects adjusted sales to decline between 5% and 13% and operating profit to drop by up to 13%. The company cited pricing pressure, intensifying competition, and upcoming patent expiries for the key ingredients in Wegovy and Ozempic in select markets outside the U.S.“This is just more evidence they are dominating the category,” Mizuho’s Jared Holz told Bloomberg of Eli Lilly’s obesity market position. “Novo is playing from behind and everyone knows it.”<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment on Stocktwits turned ‘bullish’ from ‘bearish’ over the past 24 hours, amid ‘high’ message volumes.<figure class="image"><img src="https://news.stocktwits-cdn.com/LLY_jpg_1dcca688cf.webp" alt="LLY.jpg" width="933" height="102"><figcaption>LLY's Sentiment Meter and Message Volumes on Feb. 4, 2026 | Source: Stocktwits</figcaption></figure>One user said that Lilly proved that with “a good product comes great demand.”<stembedurl>https://stocktwits.com/Bagholding_VKTX/message/643931351</stembedurl>LLY shares have gained around 25% over the past year.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/novo-nordisk-fda-higher-dose-wegovy-nvo-stock-outlook/cZbjThlR4ZM">Novo Awaits FDA Call On Higher-Dose Wegovy In Early 2026 – NVO Stock Extends Decline Pre-Market On Weak Guidance</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

LLY Stock Surges On Q4  Beat – Obesity, Diabetes Drugs Drive Strong FY26 Outlook

LLY Stock - Fourth-quarter revenue surged 43% to $19.3 billion, above Street estimates of $17.86 billion, according to Fiscal.ai data.

Fourth-quarter revenue surged 43% to $19.3 billion, above Street estimates of $17.86 billion, according to Fiscal.ai data.

OZEM
Roundhill GLP-1 & Weight Loss ETF

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest OZEM News

OZEMRoundhill GLP-1 & Weight Loss ETF